Pirarubicin

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Pirarubicin

Articles

Most recent articles on Pirarubicin

Most cited articles on Pirarubicin

Review articles on Pirarubicin

Articles on Pirarubicin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pirarubicin

Images of Pirarubicin

Photos of Pirarubicin

Podcasts & MP3s on Pirarubicin

Videos on Pirarubicin

Evidence Based Medicine

Cochrane Collaboration on Pirarubicin

Bandolier on Pirarubicin

TRIP on Pirarubicin

Clinical Trials

Ongoing Trials on Pirarubicin at Clinical Trials.gov

Trial results on Pirarubicin

Clinical Trials on Pirarubicin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pirarubicin

NICE Guidance on Pirarubicin

NHS PRODIGY Guidance

FDA on Pirarubicin

CDC on Pirarubicin

Books

Books on Pirarubicin

News

Pirarubicin in the news

Be alerted to news on Pirarubicin

News trends on Pirarubicin

Commentary

Blogs on Pirarubicin

Definitions

Definitions of Pirarubicin

Patient Resources / Community

Patient resources on Pirarubicin

Discussion groups on Pirarubicin

Patient Handouts on Pirarubicin

Directions to Hospitals Treating Pirarubicin

Risk calculators and risk factors for Pirarubicin

Healthcare Provider Resources

Symptoms of Pirarubicin

Causes & Risk Factors for Pirarubicin

Diagnostic studies for Pirarubicin

Treatment of Pirarubicin

Continuing Medical Education (CME)

CME Programs on Pirarubicin

International

Pirarubicin en Espanol

Pirarubicin en Francais

Business

Pirarubicin in the Marketplace

Patents on Pirarubicin

Experimental / Informatics

List of terms related to Pirarubicin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.

References


Linked-in.jpg